Nrx pharmaceuticals identifies significantly higher likelihood of surviving and recovering from critical covid-19 in zyesami® (aviptadil) treated patients previously administered remdesivir

Radnor, pa., nov. 29, 2021 (globe newswire) -- nrx pharmaceuticals (nasdaq: nrxp) announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with zyesami® (aviptadil) in patients with critical covid-19 and respiratory failure over existing therapies such as remdesivir. nrx asked prof. david schoenfeld, one of the world's most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.
NRXP Ratings Summary
NRXP Quant Ranking